Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial

Vaccine

Volumn 32, Issue 48, 2014, Pages 6556-6562

  Umeh, Rich ^a   Oguche, Stephen ^b   Oguonu, Tagbo ^a   Pitmang, Simon ^b   Shu, Elvis ^a   Onyia, Jude Tony ^a   Daniyam, Comfort A ^b   Shwe, David ^b   Ahmad, Abdullahi ^c   Jongert, Erik ^c   Catteau, Grégory ^c   Lievens, Marc ^c   Ofori Anyinam, Opokua ^c   Leach, Amanda ^c  

^a UNIVERSITY OF NIGERIA   (Nigeria)

^b UNIVERSITY OF JOS   (Nigeria)

^c GSK   (Belgium)

Author keywords

Children; Consistency; Immunogenicity; Malaria; RTS,S AS01; Safety

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; PARASITE ANTIBODY; PROTEIN ANTIBODY; RTS S AS01 MALARIA VACCINE; UNCLASSIFIED DRUG; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE PAIN; MALARIA; MALARIA CONTROL; MALE; MASS IMMUNIZATION; MULTICENTER STUDY; NIGERIAN; NORMAL HUMAN; PARASITE IMMUNITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION REACTION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MALARIA, FALCIPARUM; NIGERIA; STANDARDS;

ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; NIGERIA; VACCINES, SYNTHETIC;

EID: 84908577108     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.067     Document Type: Article

References (18)

1. Regules J.A., Cummings J.F., Ockenhouse C.F. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines 2011, 10:589-599.
2. The RTS,S Clinical Trial Partnership First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
3. The RTS,S Clinical Trial Partnership A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295.
4. Vekemans J., Guerra Y., Lievens M., Benns S., Lapierre D., Leach A., et al. Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials. Hum Vaccine 2011, 7:1309-1316.
5. Dellepiane N., Griffiths E., Milstien J.B. New challenges in assuring vaccine quality. Bull World Health Organ 2000, 78:155-162.
6. Kanesa-thasan N., Shaw A., Stoddard J.J., Vernon T.M. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies. Pediatrics 2011, 127(Suppl. 1):S16-S22.
7. Marshall V., Baylor N.W. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics 2011, 127(Suppl. 1):S23-S30.
8. European Medicines Agency Guideline on clinical Evaluation of New Vaccines. EMEA/CHMP/VMP/164653/2005, 2006 2006, European Medicines Agency, London.
9. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Expert Committee on Biological Standardization, fifty-second Report. Technical Report Series No. 924 2004, World Health Organization, Geneva.
10. Lell B., Agnandji S., von Glasenapp I., Haertle S., Oyakhiromen S., Issifou S., et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 2009, 4:e7611.
11. Clement F., Dewar V., Van Braeckel E., Desombere I., Dewerchin M., Swysen C., et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J 2012, 11:384.
12. Centers for Disease Control and Prevention Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40:1-25.
13. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359:2521-2532.
14. Otieno L. Efficacy of RTS,S/AS01 vaccine candidate against malaria in African infants and children 18 months post-primary vaccination. Presented at MIM 2013.
15. Leach A., Vekemans J., Lievens M., Ofori-Anyinam O., Cahill C., Owusu-Agyei S., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 2011, 10:224.
16. Newport M.J., Goetghebuer T., Weiss H.A., Whittle H., Siegrist C.A., Marchant A., et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun 2004, 5:122-129.
17. Poland G.A., Ovsyannikova I.G., Jacobson R.M., Smith D.I. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007, 82:653-664.
18. Posteraro B., Pastorino R., Di Giannantonio P., Ianuale C., Amore R., Ricciardi W., et al. The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses. Vaccine 2014, 15:1661-1669.